IVD

Top 9 Companies in the Diagnostics Market

The diagnostics space has been filled with market clearances; collaborations and a dash of M&A. MD+DI has compiled a list of the most influential companies in the market.

ArcherDX in New Companion Diagnostic Collaboration with Ayala

The Denver, CO-based company will develop companion diagnostics with Ayala, that will target cancers bearing Notch activating mutations and fusions.

Biological Dynamics Wants to Shake up Diagnostics with Verita

The San Diego-based company has received a grant from the Bill & Melinda Gates Foundation to help in its goal to develop transformative diagnostics for tuberculosis and cancer.

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

The Boulder, CO-based company is extending its blood-based lung cancer diagnostic portfolio with the acquisition of Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

Bracco Imaging ‘Ups’ its Precision Medicine Game with Blue Earth Diagnostics

The Milan, Italy based company will acquire Blue Earth Diagnostics for about $450 million.

Simple Blood Draw Detects Dangerous Pathogens

New findings show the potential clinical utility of its the Karius Test to detect pathogens causing serious infections using a simple blood draw.

CDx Diagnostics Founder and CSO Shares Company’s Journey

CDx Diagnostics began using artificial intelligence long before it became the popular or cool thing to do in medtech. Dr. Mark Rutenberg, CDx Founder and Chief Scientific Officer spoke to MD+DI about the evolution of the company and its current success.

Invitae Takes a Deeper Dive into NIPS with New M&A Target

The San Francisco-based company said it has signed a definitive agreement to acquire Singular Bio for $55 million.

Liquid Biopsy’s Saga Continues with New Financing

The Lund, Sweden-based company raised $4.1 million to accelerate commercialization of its portfolio of kits and services.

Liquid Biopsy Tests Are Becoming More Mainstream

An industry executive talks about how the market is shifting toward broader acceptance of liquid biopsy tests.

Meet Thrive: The New Kid on the Liquid Biopsy Block

Thrive Earlier Detection Corp. has raised $110 million in a series A financing and has a launch similar to Grail’s introduction into the liquid biopsy market.

Could Myriad’s New Study Results Be Game Changers For Cancer Patients?

The Salt Lake City, UT-based company made a big showing at the 2019 American Society of Clinical Oncology meeting, presenting data from three key studies.

Quest Diagnostics Data Breach Could Impact Nearly 12M Customers

The Secaucus, NJ -based company said that sometime between August 1, 2018 and March 30, 2019, an unauthorized user breached AMCA, its billing collections vendor.

Grail Presents Early Favorable CCGA Data at ASCO

Results from the Circulating Cell-free Genome Atlas study show the Menlo Park, CA-based company’s solution detected a strong signal for 12 deadly cancer types at early stages with a very high specificity of at least 99%.